DE69531290D1 - Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen - Google Patents

Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen

Info

Publication number
DE69531290D1
DE69531290D1 DE69531290T DE69531290T DE69531290D1 DE 69531290 D1 DE69531290 D1 DE 69531290D1 DE 69531290 T DE69531290 T DE 69531290T DE 69531290 T DE69531290 T DE 69531290T DE 69531290 D1 DE69531290 D1 DE 69531290D1
Authority
DE
Germany
Prior art keywords
antigen
heteropolymers
autoimmune diseases
human
occupating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69531290T
Other languages
English (en)
Other versions
DE69531290T2 (de
Inventor
Ronald P Taylor
Polly J Ferguson
Edward N Martin
William S Sutherland
Craig J Reist
Kirsten Greene
Cyd Johnson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Virginia UVA
Original Assignee
University of Virginia UVA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Virginia UVA filed Critical University of Virginia UVA
Application granted granted Critical
Publication of DE69531290D1 publication Critical patent/DE69531290D1/de
Publication of DE69531290T2 publication Critical patent/DE69531290T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69531290T 1994-02-28 1995-02-28 Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen Expired - Fee Related DE69531290T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20257294A 1994-02-28 1994-02-28
US202572 1994-02-28
PCT/US1995/002165 WO1995022977A1 (en) 1994-02-28 1995-02-28 Antigen-based heteropolymers and method for treating autoimmune diseases using the same

Publications (2)

Publication Number Publication Date
DE69531290D1 true DE69531290D1 (de) 2003-08-21
DE69531290T2 DE69531290T2 (de) 2004-05-13

Family

ID=22750436

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69531290T Expired - Fee Related DE69531290T2 (de) 1994-02-28 1995-02-28 Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen

Country Status (11)

Country Link
US (2) US5879679A (de)
EP (1) EP0743856B1 (de)
JP (1) JPH09509572A (de)
AT (1) ATE245030T1 (de)
AU (1) AU696964B2 (de)
CA (1) CA2183535A1 (de)
DE (1) DE69531290T2 (de)
DK (1) DK0743856T3 (de)
ES (1) ES2207646T3 (de)
PT (1) PT743856E (de)
WO (1) WO1995022977A1 (de)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995022977A1 (en) * 1994-02-28 1995-08-31 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
KR20020059808A (ko) 1999-11-28 2002-07-13 와이즈먼 앤드루 항체 친화도에 기초한 루프스 치료방법 및 그것의 사용을위한 스크리닝 방법과 조성물
AU4155602A (en) * 2000-11-01 2002-06-18 Elusys Therapeutics Inc Method of producing biospecific molecules by protein trans-splicing
AU2002306728B2 (en) * 2001-03-15 2007-12-13 Elusys Therapeutics, Inc. Polyclonal populations of bispecific molecules and methods of production and uses thereof
WO2003007971A1 (en) * 2001-07-17 2003-01-30 University Of Virginia Patent Foundation Improved heteropolymer complexes and methods for their use
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2003018774A2 (en) * 2001-08-29 2003-03-06 University Of Virginia Patent Foundation Therapeutic uses of complement receptor 2
US7105135B2 (en) * 2001-10-16 2006-09-12 Lockheed Martin Corporation System and method for large scale detection of hazardous materials in the mail or in other objects
AU2003241470A1 (en) * 2002-05-13 2003-11-11 Elusys Therapeutics, Inc. Purified composition of bispecific molecules and methods of production
US20040033232A1 (en) * 2002-06-13 2004-02-19 Ramberg Elliot R. Methods and compositions for in vivo clearance of pathogens
AU2003295330A1 (en) * 2002-09-16 2004-05-04 Elusys Therapeutics, Inc. Bispecific molecule comprising an anti-cr1 antibody cross-linked to an antigen-binding antibody fragment
US20040208864A1 (en) * 2002-12-27 2004-10-21 Vibeke Strand Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20050031625A1 (en) * 2003-03-28 2005-02-10 Elusys Therapeutics, Inc. Methods and compositions for conversion of antibody activity
WO2004089422A2 (en) * 2003-03-30 2004-10-21 La Jolla Pharmaceutical Co. Methods of treating and monitoring systemic lupus erythematosus in individuals
AU2004256021A1 (en) 2003-05-09 2005-01-20 University Of Massachusetts Non-human animals expressing heterologous complement receptor type 1 (CR1) molecules on erythrocytes and uses therefor
WO2005116071A2 (en) * 2004-05-28 2005-12-08 University Of Massachusetts Snares for pathogenic or infectious agents and uses related thereto
AU2005302312A1 (en) * 2004-10-29 2006-05-11 Elusys Therapeutics, Inc. Use of CR1-binding molecules in clearance and induction of immune responses
EA014900B1 (ru) 2005-11-07 2011-02-28 Зе Скрипс Ресеч Инститьют Композиции и способы контроля специфичности передачи сигналов, опосредуемой тканевым фактором
US8828077B2 (en) * 2006-03-15 2014-09-09 Medinol Ltd. Flat process of preparing drug eluting stents
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
CN108129554A (zh) 2010-08-10 2018-06-08 洛桑聚合联合学院 红细胞结合性治疗剂
FR2968304B1 (fr) * 2010-12-01 2014-03-14 Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic Nouveaux epaississants cationiques, exempts d'huile et de tensioactifs, procede pour leur preparation et composition en contenant.
CN110075284A (zh) * 2012-02-15 2019-08-02 洛桑聚合联合学院 红细胞结合性治疗剂
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
WO2015140648A2 (en) 2014-02-21 2015-09-24 Ecole Polytecnique Federale De Lausanne (Epfl) Epfl-Tto Glycotargeting therapeutics
US11253579B2 (en) 2017-06-16 2022-02-22 The University Of Chicago Compositions and methods for inducing immune tolerance
US20200247903A1 (en) * 2017-10-20 2020-08-06 Csl Ltd. Method

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8869291A (en) * 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
WO1995022977A1 (en) * 1994-02-28 1995-08-31 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same

Also Published As

Publication number Publication date
US20020103343A1 (en) 2002-08-01
US5879679A (en) 1999-03-09
WO1995022977A1 (en) 1995-08-31
AU696964B2 (en) 1998-09-24
CA2183535A1 (en) 1995-08-31
EP0743856A1 (de) 1996-11-27
PT743856E (pt) 2003-12-31
DE69531290T2 (de) 2004-05-13
AU1967795A (en) 1995-09-11
DK0743856T3 (da) 2003-11-10
JPH09509572A (ja) 1997-09-30
ATE245030T1 (de) 2003-08-15
EP0743856A4 (de) 2000-04-12
EP0743856B1 (de) 2003-07-16
ES2207646T3 (es) 2004-06-01

Similar Documents

Publication Publication Date Title
DE69531290D1 (de) Antigen-besierende heteropolymere zur behandlung von autoimmunkrankheiten mittels diesen
ATE248605T1 (de) Für e-selectin und p-selectin spezifische kreuzreaktive monoklonale antikörper
ATE347565T1 (de) Bispezifischer antikörper zur effektiven behandlung von b-zell lymphomen und zellinien
ATE403680T1 (de) Herstellung tetravalenter antikörper
FI924819A0 (fi) Chimaera anti-icam-i-antikroppar foer maenniskobruk, foerfaranden foer deras framstaellning samt deras anvaendning
ZA946767B (en) Monocional antibodies having property of causing apoptosis.
DE68925226D1 (de) Monoklonale Antikörper
NO883306D0 (no) Farmasoeytisk aktive konjugater med forbedret bindingsspesifisitet for kroppsvev.
ATE205532T1 (de) Zellzyklus-unabhängige, gliomaoberflach- spezifische, menschliche monoklonale antikörper
FI973484A0 (fi) Menetelmä immuunivasteen stimuloimiseksi
PT954333E (pt) Receptores soluveis de linfotoxina-beta, anticorpos de receptores de anti-linfotoxina e anticorpos de ligandos de anti-linfotoxina como agentes terapeuticos para o tratamento de doencas imunologicas
ATE484294T1 (de) Anti-interleukin-9 antikörper oder anti- interleukin-9 rezeptor antikörper zur behandlung von bronchialem hyperreaktionsvermögen
SE8800886D0 (sv) Immunoglobulin conjugates
ATE100331T1 (de) Verfahren zur behandlung von septischem schock.
ATE70311T1 (de) Monoklonale antikoerper gegen menschliche igerezeptoren auf lymphocyten, diese antikoerper produzierende hybridomas und reaktionsansaetze zum gebrauch dieser antikoerper.
ATE173503T1 (de) Die verwendung des leukozyten adhäsionsmolekül-1- aus endothelzellen und antikörper dagegen in der behandlung von asthma

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee